Imaging Center M&A Data Room: Selling a Radiology Group in the Roll-Up Wave (2026)

Last updated: July 2026

Quick answer: An imaging center M&A data room is the secure, access-controlled environment a physician-owned radiology group uses to run its sale — and in this asset class the deal is decided by the buyer's Big Three: payor-contract survival, radiologist retention, and fleet age. All three are answered with documents, not assurances. A buyer barely cares about your building; it underwrites whether your above-market payer rates survive a change of control, whether your radiologists are locked in against a national shortage, and how much replacement capex your scanners are hiding. On top of that sits the regulatory transfer stack — the certificate of need in CON states, the Medicare IDTF enrollment, radioactive-materials and MQSA licenses. The group that walks in with a room organized around those questions closes at its multiple; the group that emails PDFs gets re-traded. And because diligence files touch PHI-adjacent data, your data-room provider should be willing to sign a BAA — Peony does.

I'm Sean Yu, co-founder of Peony, a data room company serving 5,900+ customers across M&A, fundraising, and healthcare deals. I don't read scans — but I've watched a lot of physician-practice sales move through data rooms, and outpatient imaging is one of the clearest cases of a single truth: you are not selling equipment, you are selling an operation that transfers with contracts, licenses, and people. A buyer will pay a full multiple for a group whose payer rates, radiologist panel, and fleet are documented and provable, and it will grind that same group down one re-trade at a time if those three things arrive as a scramble of emailed PDFs three weeks into exclusivity. Get the room organized around the Big Three plus the transfer stack, and the deal closes where you underwrote it. Leave it scattered, and the market reprices it for you.

The window is real, and the buyers are professionalized. US Radiology Specialists renamed itself Lumexa Imaging on July 8, 2025 and IPO'd on Nasdaq as LMRI, raising $462.5 million — the biggest imaging-consolidation story of the cycle. RadNet has directed over $340 million to acquisitions in 2026 alone, as reported. And Akumin emerged from Chapter 11 in February 2024 as a private company under Stonepeak. These are not casual acquirers; they run disciplined diligence, and they judge your room against an institutional standard. This post is the sell-side playbook for meeting that standard.

This is the imaging-center asset class specifically. It sits in the same healthcare-M&A family as our medical device M&A data room and medical equipment sale data room guides — sibling deals with their own document tapes — and it's the outpatient-diagnostic cousin of our skilled nursing facility data room guide, where the same principle holds: the business transfers with a license and a liability tail, not just a deed. If you haven't picked a banker yet, that's our best healthcare M&A advisors guide; if a capital partner rather than a strategic is your buyer, our independent sponsor and healthcare capital partners guide covers that path. This post is the room that runs the deal once you know who's buying.

Who is actually buying imaging centers in 2026?

A handful of professionalized national platforms — public strategics, PE-backed roll-ups, and post-bankruptcy consolidators — are doing the bulk of the buying, and they all run disciplined, document-driven diligence. If a platform has approached you, you're not negotiating with an amateur, and your room has to reflect that.

Here's the consolidation map, hedged where a figure rests on trade-press reporting rather than a primary filing.

RadNet (Nasdaq: RDNT) is the public strategic. It operated roughly 435 outpatient imaging centers across 11 states as of its Q1 2026 reporting — a moving target through the year as tuck-ins closed — with Q1 2026 revenue of about $575.6 million, up 22.1% year over year (as reported). RadNet has been the most acquisitive name in the space, with reporting that it directed over $340 million to acquisitions in 2026 alone, including a French imaging-AI firm and, earlier, breast- and ultrasound-AI vendors; in January 2026 it added a 13-center Southwest Florida group (a LucidHealth division) said to bring roughly $100 million in annual revenue. A public buyer brings disclosure discipline and a clear appetite, but it also means your deal terms may surface in its filings.

Lumexa Imaging (Nasdaq: LMRI) is the headline story. Formed in 2018 by Charlotte Radiology and Welsh, Carson, Anderson & Stowe as US Radiology Specialists, it renamed to Lumexa Imaging effective July 8, 2025 and went public on Nasdaq, raising $462.5 million — roughly double its original target. As of September 30, 2025 it reported 184 centers across 13 states, including eight health-system joint-venture partnerships — the second-largest outpatient imaging footprint in the country, grown from 20 centers via a mix of acquisitions and de novo builds. A JV-heavy platform brings health-system relationships and a specific referral posture to the table.

SimonMed is a large PE-backed operator reporting 170-plus locations and around 200 radiologists, and it has been notably active in AI and whole-body-MRI screening. Akumin took the hardest road: it filed Chapter 11 in October 2023, emerged in February 2024 as a private company under Stonepeak Capital after shedding roughly $470 million of debt, and reframed as a turnaround. Rayus Radiology, backed by Wellspring Capital, remains active though quieter on new deals in 2026. Beyond the named platforms, private-equity activity in diagnostic imaging was reported as "steady" through 2025 with a dozen-plus deals.

The through-line: every one of these buyers wants the same three answers, and none of them will take your word for it. That's what the rest of this post is about.

The Big Three at a glance: what actually decides the deal

Before the section-by-section detail, here's the compressed version — the small number of questions that move your price, and the reality behind each. Read the middle column twice; that's where deals re-trade.

The multiple you get is a function of how convincingly your room answers these. Advisors publish EBITDA ranges, but no table sets your price — the documents do.

Why does payor-contract survival kill or make the deal?

Because your above-market payer rates are often the real asset you're selling, and a change of ownership is precisely the moment a payer can take them away. This is Big Three #1, and it's the workstream that most quietly destroys deal value.

Start with the mechanic. Almost every commercial payer contract contains a change-of-control provision, an assignment clause, or both. Advisors put the stakes as directly as it gets: "Each contract has an assignment clause, a change of control clause, or both, and the deal cannot fund without written payer consent or an opt-out election filed in time to maintain in-network status." That's the kill-shot. If the paperwork to preserve in-network status isn't filed correctly and on time, the acquired centers can fall out of network — and the revenue the buyer paid for simply stops.

Then there's the subtler danger: repricing. When a buyer seeks a payer's consent to assignment, the payer can use that leverage to reprice your rates down to its current, lower fee schedule. If your group has been enjoying legacy above-market rates — which is often exactly why you're an attractive target — consent can erase them, and the EBITDA the buyer underwrote evaporates post-close. That's why sophisticated buyers treat your rate stack and payer-consent risk as a top diligence workstream, and why they'll comb every contract for the clause that lets a payer reprice.

The deal structure changes the exposure. In an asset sale, contracts don't transfer automatically — they must be assigned, which typically triggers the consent requirement and puts every anti-assignment clause in play. In a stock or equity sale, the contracts stay with the same legal entity, so anti-assignment provisions are generally not implicated — but change-of-control clauses can still fire, especially those drafted to capture indirect or ultimate ownership changes. There's no structure that makes the payer question disappear; there's only the version of it you're dealing with.

What the room has to do: lay out the payer contracts one by one — the rate stack, the specific change-of-control and assignment language in each, in-network status, and the consent or notice steps required. A buyer's counsel is going to build exactly that map anyway. The seller who hands it over organized, with the risky clauses already flagged and a consent plan sketched, keeps control of the narrative; the seller who lets the buyer discover a repricing landmine in week four watches it become a re-trade.

How do buyers evaluate radiologist retention, and how do you answer it?

Retention is the buyer's number-one question because in an imaging group the radiologists are the revenue — and you answer it with signed agreements and a demonstrably stable panel, never with assurances. This is Big Three #2, and the market backdrop explains why buyers press so hard on it.

The workforce data is stark. Radiologist attrition more than doubled from 2014 to 2022, rising from 1.1% to 2.5% per year, with the jump accelerating around 2020 (Neiman HPI). On the supply side, the radiologist workforce is projected to grow only 25.7% between 2023 and 2055 assuming no growth in residency positions, while imaging utilization is projected to rise 16.9% to 26.9% over the same period — demand outpacing supply. The Neiman researchers project the shortage will persist — as they put it, it is "not projected to get worse, nor will it likely improve in the next three decades without effective action" — with a further demand driver in the 75-and-older population projected to grow enormously through 2055. In plain terms: radiologists are scarce and getting scarcer, so a buyer acquiring your group is acquiring your ability to keep reading studies — and it will not pay full price for a panel that might walk.

That scarcity cuts in your favor if you've locked your panel down. A group with an owned, contracted radiologist team is worth more precisely because coverage is hard to replace; a group leaning heavily on teleradiology to fill gaps invites a diligence flag — the buyer will read the teleradiology contracts, turnaround SLAs, per-read costs, and subspecialty coverage to judge how fragile the coverage really is.

Here's how you answer, concretely, in the room:

• The agreements themselves. Every radiologist's employment or independent-contractor agreement, current and signed, with compensation terms a buyer can model.
• Retention that survives closing. Employment agreements or new-hire terms that keep key readers in place post-close — this is often a signing condition, not a nicety.
• Enforceable non-competes where state law allows. More on this below, because the legal ground shifted in 2026 — but a non-compete that actually binds is a retention lever in the states that permit it.
• A coverage model that isn't one departure from collapse. Subspecialty depth, call schedules, and cross-coverage that show the operation survives a single radiologist leaving.
• Clean turnover history. Low, explainable historical attrition is itself evidence against the market trend.

The seller who stages this file well lets a buyer get comfortable fast. The seller who treats "our rads are happy" as sufficient hands the buyer a reason to discount for retention risk — against a backdrop where the buyer already knows the whole specialty is short-staffed.

A 2026 wrinkle: the FTC non-compete rule is gone

One legal change reshaped the retention conversation this year, and it's worth stating precisely because it's easy to get wrong. The FTC's Non-Compete Clause Rule is dead. The FTC formally removed 16 CFR Part 910 from the Code of Federal Regulations, effective February 12, 2026, conforming the CFR to the court's vacatur of the rule — the final procedural step after a Texas federal court blocked it in 2024 and the FTC dismissed its appeals in 2025. The agency has shifted to case-by-case enforcement rather than a categorical ban.

The net for your deal: physician non-competes are now governed entirely by state law, which varies widely and is still evolving. Because the federal ban never actually took effect, sellers in states that permit non-competes retain that retention lever — a buyer can still require enforceable non-competes as a condition. Sellers in states that ban them (California, for instance) cannot promise that lever and have to demonstrate retention another way — compensation, rollover equity, culture, leadership roles. Know which regime your centers sit in before a buyer asks, because "we'll sign non-competes" is an empty promise in a state that won't enforce them.

Does aging MRI equipment reduce the sale value?

Yes — an aging fleet is rarely a deal-breaker, but it's almost always a price adjustment, because buyers deduct near-term replacement capex from the purchase price and scrutinize the service costs on old scanners. This is Big Three #3, the most concrete of the three, and the one you can quantify most cleanly in the room.

Here's how a buyer underwrites your fleet. It looks at each scanner's age, make, model, coverage level, and remaining service-contract term, because service contracts are the largest predictable equipment expense in an imaging operation. Industry sources report OEM (Siemens Healthineers, GE HealthCare, Philips) MRI service contracts running roughly $150,000-$350,000 per year — the lower end for 1.5T systems, the higher for 3.0T — and note that OEM coverage typically costs 40-80% more than third-party ISO providers. So two MRIs past ten years old tell a buyer two things: replacement capex is coming, and the service costs to keep them running until then may be rich. The buyer models that and subtracts it. That's a haircut, not a kill.

You blunt the haircut with documentation. The equipment schedule in your room should carry, for each scanner:

• Make, model, field strength, and install date (age is the first number a buyer looks for).
• The service contract — OEM or ISO, coverage level, annual cost, and remaining term.
• Service and downtime history — a well-maintained aging machine reads very differently from a neglected one.
• Any transferable warranties and any recent capex refresh — recent investment is the single best defense of the multiple.
• Utilization by modality, tying the equipment back to the revenue it produces.

The contrast is the whole point. A group that presents an honest, well-maintained fleet with recent capex and transferable coverage defends its multiple — the buyer can price the capex and move on. A group that lets the buyer discover an off-contract, decade-old scanner in diligence hands it a re-trade, because now the buyer wonders what else wasn't disclosed. On equipment, transparency is worth more than youth.

What's in the regulatory transfer stack for an imaging deal?

The regulatory transfer stack is the set of licenses and enrollments that don't move automatically when your group sells — each one a transaction consent that has to be transferred, amended, or re-issued — and mishandling any of them can gap your billing or stall your close. This is the layer beneath the Big Three, and it's where imaging deals share DNA with other licensed-healthcare transactions: the business transfers with its licenses, not just its assets.

Certificate of need (CON). In 35 states plus Washington, D.C. — per the National Conference of State Legislatures, as of 2025 — some form of CON law is on the books, and many programs specifically regulate major imaging equipment like MRI, CT, and PET scanners. The variation is dramatic and worth a concrete contrast: North Carolina requires a CON to acquire a fixed MRI scanner (the state issued fixed-MRI CONs to hospital systems as recently as late 2025), while Georgia does not regulate MRI or CT under CON at all. For a seller, this cuts two ways. Where CON applies, your approved equipment slots are a scarce, transferable asset that limits new competition — a genuine value driver a buyer will pay for. But the transfer or re-issuance of that CON is a regulatory step the parties don't fully control, so it becomes a closing condition and a timeline risk that has to be sequenced into the deal calendar. The room holds the CON paperwork and the transfer analysis; a buyer's counsel maps the process early. And the CON landscape is shifting — several states have been scaling their programs back — so the current status in your state, on the current NCSL data, is what matters.

Medicare IDTF enrollment and the CHOW. Independent diagnostic testing facilities enroll in Medicare via CMS-855B, and there's a hard timing rule sellers and buyers both need to internalize: changes in ownership, changes of location, changes in general supervision, and adverse legal actions must be reported to the Medicare Administrative Contractor within 30 calendar days; all other changes within 90 calendar days. The bigger structural fork is the change of ownership itself. Under the CHOW framework at 42 CFR 489.18, a formal change of ownership assigns the seller's Medicare billing number and provider agreement to the buyer — continuity of billing, but the buyer inherits the agreement's liabilities and any overpayment exposure. Alternatively, in an asset sale where the buyer does not accept assignment, the buyer must enroll as a new supplier (a new 855B, a new billing number), which can open a revenue gap between closing and new billing privileges. Billing continuity versus clean liability is a core structuring negotiation, and the enrollment file — current 855B, PTAN, supervision arrangements, and the CHOW plan — belongs in the room. (Note too that adding new CPT/HCPCS codes of a similar type amends the 855B without a new site visit, while different procedure types or supervision levels require a new one — relevant if the buyer plans to expand modalities.)

Radioactive-materials licensing for nuclear medicine and PET. If your group runs nuclear medicine or PET, it holds a radioactive-materials license — from the NRC or, more often, from an Agreement State. As of March 2025 there were 39 NRC Agreement States administering roughly 88% of US radioactive-materials licenses. These licenses are transaction consents: a change of ownership requires the license to be amended or reissued, and that has to be on the closing checklist and in the room.

MQSA and ACR accreditation for mammography. Any mammography line is a hard diligence gate. Mammography facilities must be MQSA-certified (an FDA program), and — a detail worth knowing — the FDA maintains a public, ZIP-searchable database of MQSA-certified facilities, updated weekly. A buyer can and will check it, and any lapse or inspection deficiency is public and material. Layer on ACR accreditation, the dominant modality accreditation required by many payers, and you have a compliance file that has to be current and clean before it goes in the room, because a buyer treats an accreditation gap as both a revenue risk and a red flag about how the practice is run.

The pattern across all four: none of these transfers on its own, each has its own clock and its own consent, and the seller who has assembled the license file — current status, expiration dates, transfer requirements — lets the deal run on schedule. The seller who treats licensing as a closing-week afterthought is the one whose deal slips.

How do the partner economics work — rollover, cash, and the holdout?

Partner economics are usually decided by a rollover-versus-cash split that varies by each partner's time horizon, and by resolving any holdout in the governance documents before a buyer sees the cap table. In a physician-owned group, this is where deals get personal, and it's a workstream a generic checklist ignores entirely.

Rollover versus cash. Platform deals almost always ask sellers to roll part of their proceeds into equity in the acquiring platform rather than take all cash — the classic "second bite of the apple," where partners bet on a payday when the platform itself sells again. Rollover in healthcare PE deals is commonly cited at 10-30% of practice value, and advisors report that 2026 deals push larger rollover — roughly 20-40% — with longer earn-outs, regulatory escrows, and tighter management incentive plans than the deals of 2022. A majority recapitalization (selling 60-80%, keeping 20-40%) is the typical platform structure. The right split for any individual partner usually comes down to age and horizon: a partner five years from retirement tends to value cash certainty and a clean non-compete; a younger partner values the rollover upside and a leadership seat in the bigger platform. There's no universal answer — but the rollover only makes sense if the buyer is a credible compounder, which is itself something your diligence should test.

The partner who won't sell. A holdout is a deal-killer a buyer will find, so you resolve it up front. Your operating or shareholders' agreement governs the fight — drag-along rights, approval thresholds, and buy-sell provisions determine whether a majority can bind a dissenting partner and on what terms. A buyer underwriting the group wants a clean, bindable signature block; a partner who can block the deal, or who leaves angrily and takes referral relationships out the door, is a retention and revenue risk that reprices the transaction. The common resolutions are a negotiated buyout of the holdout, a larger rollover to bring them onside, or a defined role that keeps them engaged. Whatever the path, sort it early and paper it, so the ownership and governance file in the room reads clean when the buyer's lawyers open it. Discovering a partner dispute in diligence is one of the fastest ways to lose a buyer's confidence.

How do you keep the sale invisible to referrers and staff?

With staged disclosure and a data room that gates who sees what, because your referring-physician book is the most fragile asset in the deal and it can evaporate the moment the process leaks. Confidentiality isn't a nicety in an imaging sale — it's a value-preservation strategy.

Here's why the referral base is so fragile: it's a relationship, not a contract. Your volume comes from referring physicians who send patients to your centers out of habit, trust, and convenience — and a referrer who hears you're selling can move that volume to a competitor overnight, with nothing to stop them. Staff are the second exposure: a technologist or front-desk lead who fears what a new owner means for their job can walk, and in a tight labor market that hurts. So the entire process runs on need-to-know — a small deal team, code names for the transaction, and disclosure that widens only as certainty rises.

The data room is the instrument that makes staged disclosure real:

• An NDA gate in front of everything. No counterparty sees a single document until a non-disclosure agreement is signed.
• Permission groups behind the gate. A financial buyer, a strategic competitor, and a lender don't all see the same files. Early on, a buyer sees financials and operations; the staff rosters, individual radiologist compensation, and referral-source detail stay dark until late-stage exclusivity, when the deal is real enough to justify the exposure. Programmatic permission groups do this in one room without spinning up parallel copies that fragment the audit trail.
• Per-viewer watermarks. Every page carries the identity of the person viewing it, so a leaked document traces to a name. That alone changes how carefully a counterparty handles your files.
• Analytics that show intent. Seeing who opened what, and for how long, tells you which buyers are serious and what they're worried about — so you can address an objection before it becomes a re-trade.

The competitive risk here is acute because your most likely buyers — RadNet, Lumexa, SimonMed — may already operate in or near your market. Handing a competing platform your referral-source detail and radiologist roster early, before you know the deal is real, is handing a competitor a roadmap. Staged disclosure behind a gated room is how you let a serious buyer diligence you without letting the market — or a rival — learn you're for sale before you're ready. Referrers and staff should find out on your timeline.

What actually goes in an imaging center data room?

Organize the room around the buyer's Big Three plus the regulatory transfer stack, and diligence moves fast; organize it as a document dump, and the buyer builds its own re-trade narrative in the gaps. Here's the folder map I'd build, mirroring the way a buyer actually reads a radiology group.

• 1. Payer contracts and revenue (Big Three #1). Every commercial and government payer agreement; the rate stack by payer and modality; each contract's change-of-control and assignment clauses flagged; in-network status; and a consent/notice plan. This is the folder a buyer's counsel lives in.
• 2. Radiologists and clinical staffing (Big Three #2). Signed employment and independent-contractor agreements; compensation; non-competes (with a note on state enforceability); call schedules and cross-coverage; subspecialty coverage; and any teleradiology contracts with SLAs and per-read costs. Historical turnover data.
• 3. Equipment fleet (Big Three #3). A scanner-by-scanner schedule: make, model, field strength, install date, service contract (OEM/ISO, cost, remaining term), service and downtime history, transferable warranties, and recent capex.
• 4. Regulatory and licensing (the transfer stack). State facility and professional licenses; any certificate of need and its transfer analysis; the Medicare IDTF enrollment (CMS-855B), PTAN, and CHOW plan; radioactive-materials licenses for nuclear medicine/PET; MQSA certificates and ACR accreditation for mammography, with current inspection status; and OSHA/state radiation-control records.
• 5. Financials and quality of earnings. Three years of financial statements plus a QofE-ready trial balance and adjustments; payor-mix and modality-volume detail; accounts-receivable aging; and a normalized EBITDA bridge. (More on QofE below.)
• 6. Corporate, governance, and partner economics. Formation documents, the operating/shareholders' agreement (drag-along, buy-sell, approval thresholds), cap table, and any partner-buyout or rollover term sheets.
• 7. Real estate and leases. Facility leases (and any related-party lease terms a buyer will scrutinize for FMV), and any owned real estate.
• 8. HR, compliance, and corporate records. Employee census, benefits, the compliance program, HIPAA policies, prior audits, and litigation history.

Two disciplines make this room deal-grade rather than a pile of files. First, de-identify anything PHI-adjacent — volume and case-mix analyses should use Safe Harbor datasets, and any file that must contain PHI stays behind a signed BAA and tight permissions (see the HIPAA section below). Second, stage it before the request list lands. Diligence formally starts when the buyer's counsel sends a document request; the winning move is to have the package built and indexed first, so on day one the buyer finds it organized and waiting. AI auto-indexing sorts a bulk upload of hundreds of contracts, license files, and cost reports into that structure in minutes, which is what makes a deal-grade imaging room buildable on a transaction timeline instead of a month of manual foldering. Across our 5,900+ customers, the pattern I see most is that the organized seller surfaces its own payer or fleet problems early — while it still has leverage and a credible price — rather than letting a buyer surface them later as leverage against it.

Do you need a quality-of-earnings report, and how long does the deal take?

A quality-of-earnings (QofE) report is a buy-side or sell-side financial analysis that normalizes your EBITDA — stripping out one-time items, owner add-backs, and non-recurring revenue to show a buyer the real, sustainable earnings the price is built on. On the sell-side, commissioning your own QofE before you go to market is increasingly standard for a group of any size: it lets you find and fix the adjustments a buyer would otherwise use against you, and it signals that your numbers will survive scrutiny. The QofE team is one of the counterparties that lives in your data room — and with Peony they view for free as unlimited free viewers, so a QofE engagement doesn't add per-seat cost.

On timeline: an imaging-center sale to a professional buyer typically runs several months from first engagement to close — a marketed process with a banker adds time up front for preparation and buyer outreach, and the regulatory transfer stack (CON transfer, license amendments, payer consents) can extend the back end because those approvals aren't fully in the parties' control. The single biggest lever on speed is room readiness: a seller whose payer, radiologist, fleet, and license files are staged and indexed on day one can compress diligence dramatically, while a seller who assembles the room reactively drags the process out and invites re-trades. For the general shape of the phases, our due diligence timeline guide walks the standard M&A calendar; the imaging-specific point is that the regulatory consents are what make the tail unpredictable, so start them early.

MSO versus full acquisition, and the hospital-JV referral question

Two structural forks deserve a note because they change what "selling" even means. In a full acquisition, the buyer takes the whole practice — assets, contracts, and (in a CHOW or stock deal) the provider relationship. In an MSO (management services organization) model, the arrangement splits the practice: the physicians retain the clinical entity (often required by corporate-practice-of-medicine rules in many states, which restrict non-physician ownership of medical practices), while the MSO owns the non-clinical assets and provides management services under a long-term agreement. The MSO structure is common in PE physician deals precisely because it navigates those ownership restrictions — and it changes your diligence, because now the management services agreement and the friendly-PC structure are central documents in the room.

The hospital-JV path raises its own question sellers should ask directly: will the JV steer my referrals? A health-system joint venture can bring referral stability and a strategic partner, but it can also capture or narrow your referral base — directing volume toward the system and away from independent referrers — and it may constrain your payer leverage. That's not inherently bad; it's a trade of independence for stability. But it's a term to negotiate explicitly and understand before signing, not discover afterward. The JV agreement, and any referral or steering provisions in it, belong in the room and deserve careful legal review.

Why must a data-room provider sign a BAA for a healthcare deal?

Because your diligence files contain PHI-adjacent data, which makes any vendor that hosts them a HIPAA business associate — and a business associate must operate under a signed Business Associate Agreement (BAA). This is a healthcare-specific requirement most generic file-sharing tools aren't built to meet, and it's a question you should ask your provider directly. Peony signs BAAs on request.

Here's the framework. Even in a well-run sell-side process, some files will touch protected health information — think patient volume and case-mix detail, QA and accreditation records, or claims data. Any platform hosting that information is, under HIPAA, a business associate of your practice, and HIPAA requires a BAA between the covered entity and its business associates. So the clean approach to your room is two-layered:

• De-identify wherever possible. HIPAA's Safe Harbor method de-identifies data by removing all 18 specified identifiers — names; most geographic detail below the state level; all date elements except year (with ages 90+ aggregated); phone, fax, and email; Social Security, medical-record, and account numbers; device and biometric identifiers; full-face images; and any other unique identifying code — plus the requirement that you have no actual knowledge the remaining data could still identify someone. Volume and case-mix analyses should run on Safe Harbor datasets, which carry no PHI and can sit in the room with normal permissions.
• Gate the rest behind a BAA and tight access. For any file that genuinely must contain PHI, keep it behind a signed BAA with your data-room provider and restrict access to the narrowest possible group.

The practical takeaway for anyone evaluating a room for a healthcare deal: ask your provider whether they will sign a BAA. If they won't, they can't lawfully host PHI for you, and you're forced into awkward workarounds. Peony does sign BAAs on request — so you can run the de-identified analysis openly and keep the genuinely protected files behind the agreement and a tight permission wall, in one room.

How much does a data room cost, and when do you need an enterprise VDR instead?

For a physician-owned imaging group, a flat-rate room is the right structure and it costs far less than legacy per-page platforms — but a Lumexa-scale platform sale run by bankers will use an enterprise VDR, and I'll tell you honestly where the line is.

Peony's pricing is built for the deal team you actually have. The Data Room plan is $52 per user per month — the most popular tier — and the Deal Team plan is $64 per user per month with a four-seat minimum. Critically, buyers, lawyers, and quality-of-earnings teams view for free as unlimited free viewers, so you pay for your own seats, not for headcount on the other side of the table and not for the thousands of pages a radiology deal renders into. That's the right shape for imaging M&A: the document set is heavy — payer contracts, equipment schedules, cost reports, survey and accreditation files — but the deal team is small, typically a few partners, a banker, and counsel. Legacy per-page or per-deal platforms like Datasite and Intralinks can bill tens of thousands of dollars on that same document set, because they price the pages, not the people. For a deeper breakdown of how VDR pricing models compare, our virtual data room cost guide lays out per-page versus flat-rate structures.

Where you need something else — the honest carve. If you're a Lumexa-scale platform selling to public markets or a strategic acquirer, run by an investment bank that mandates a specific enterprise VDR with its own procurement and integration requirements, that's the enterprise-platform lane, and Datasite or Intralinks is often the default there — I'm not going to pretend a flat-rate room is what a $1-billion-plus platform IPO or sale runs on. But that's a narrow slice of the market. The overwhelming majority of imaging deals are the one-to-ten-site, physician-owned sell-side — the group that got a call from a platform and needs to run a professional, confidential process without lighting tens of thousands of dollars on fire for software. That's exactly where a flat-rate room wins, and it's why we serve 5,900+ customers across deals of that shape without pretending we're the right tool for every transaction. Match the room to the deal: for the physician-owned imaging sale, flat-rate is the fit.

Frequently asked questions

Should I sell my imaging group to a PE-backed platform or do a hospital joint venture?

It depends on whether you want the highest cash multiple now or long-term referral protection, because the two paths optimize for different things. A PE-backed platform — RadNet, Lumexa, SimonMed, Rayus — typically pays a full multiple, wants a rollover stake and a radiologist-retention lock, and runs your group as a portfolio asset toward a second exit. A hospital joint venture usually trades a lower headline price for referral stability, but it can steer or capture your referral base and narrow your payor leverage. There's no universal answer; the deal is decided by what your data room proves about payor-contract survival, radiologist retention, and fleet age. Document those three and you close at your multiple; email PDFs and you re-trade.

How do RadNet, SimonMed, and US Radiology differ as buyers of independent groups?

They're all professionalized national platforms, but they differ in scale, structure, and ownership. RadNet (Nasdaq: RDNT) ran roughly 435 outpatient centers across 11 states as of its Q1 2026 reporting and directed over $340 million to acquisitions in 2026 alone, as reported — a public strategic that also buys imaging-AI. US Radiology Specialists renamed itself Lumexa Imaging on July 8, 2025 and IPO'd on Nasdaq as LMRI, raising $462.5 million; as of September 30, 2025 it reported 184 centers across 13 states including eight health-system joint ventures — the second-largest US footprint. SimonMed reports 170-plus sites and is PE-backed. The three want the same answers, but a public buyer's disclosure discipline and a JV-heavy platform's referral posture change your negotiation.

Should physician partners take equity rollover or cash out in a PE deal?

Most platform deals require a mix, so the real question is how much of each and whether the second bite is credible. Rollover equity in healthcare PE deals is commonly cited at 10-30% of practice value, and advisors report 2026 deals pushing larger rollover (roughly 20-40%), longer earn-outs, and tighter incentive plans than 2022 deals. Partners who roll bet on a 'second bite of the apple' when the platform sells again. The right split usually turns on time horizon — a partner near retirement values cash and a clean non-compete; a younger partner values rollover upside. The rollover only matters if the buyer is a credible compounder, itself a diligence question your data room helps answer.

How do I handle a physician partner who doesn't want to sell?

You resolve it in the governance documents before the buyer ever sees the cap table, because an unresolved holdout is a deal-killer a buyer will find. Start with the operating or shareholders' agreement: drag-along rights, approval thresholds, and buy-sell provisions determine whether a majority can bind a dissenter and on what terms. A buyer wants a clean, bindable signature block — a partner who can block signing, or who leaves angrily with referral relationships, is a retention and revenue risk that reprices the deal. Common resolutions: a negotiated buyout, a larger rollover to align them, or a role that keeps them engaged. Sort it early and paper it, so the ownership file in the data room reads clean.

How do I keep the sale invisible to referring physicians and staff?

With staged disclosure and a data room that gates who sees what, because your referring-physician book is the most fragile asset in the deal and it evaporates if the process leaks. The referral base is a relationship, not a contract — a referrer who hears you're selling can move volume overnight. So the deal runs on need-to-know: a small deal team and a room where the buyer sees financials and operations before anyone sees staff rosters or referral detail. Behind an NDA gate, permission groups scope each counterparty to its lane, per-viewer watermarks stamp every page, and the most sensitive files stay dark until late-stage exclusivity. Referrers and staff should learn on your timeline, not the market's.

What documents go in a data room for a radiology practice sale?

Organize the room around the buyer's Big Three — payor contracts, radiologist retention, fleet age — plus the regulatory transfer stack, and the deal moves. Concretely: the payer contract file (every commercial and government agreement, the rate stack, and each change-of-control or assignment clause); the radiologist file (employment and contractor agreements, compensation, non-competes, call schedules, teleradiology contracts, subspecialty coverage); the equipment fleet schedule (each scanner's make, model, install date, service contract, remaining term); the regulatory stack (state licenses, any certificate of need, Medicare IDTF enrollment via CMS-855B, radioactive-materials licenses, MQSA and ACR accreditation); the financials (three years plus a quality-of-earnings-ready trial balance and payor-mix detail); corporate, governance, and real-estate documents; and an HR file. De-identify anything PHI-adjacent.

What should I expect selling an imaging center in a certificate-of-need state?

Expect the certificate of need to be both a moat and a closing condition, with rules that differ sharply by state and modality. Per the National Conference of State Legislatures, 35 states plus Washington, D.C. maintained some form of CON law as of 2025, many regulating major imaging equipment like MRI and CT. The contrast is concrete: North Carolina requires a CON to acquire a fixed MRI scanner, while Georgia does not regulate MRI or CT at all. In a CON state, your approved equipment slots are a scarce, transferable asset that limits competition — but the transfer is outside the parties' control, so sequence it into the calendar. The data room holds the CON paperwork; counsel maps it early.

Will my payor contracts get repriced under new ownership?

They can be, and that risk is often the single largest threat to your deal value, because your above-market payer rates may be the real asset. Almost every commercial payer contract has a change-of-control provision and an assignment clause; advisors put it bluntly — the deal cannot fund without written payer consent or an opt-out election filed in time to maintain in-network status. The danger: seeking a payer's consent to assignment lets it reprice your rates down to its lower fee schedule, and the EBITDA the buyer paid for evaporates post-close. Your rate stack and payer-consent risk is a top diligence workstream, and the room has to lay it out contract by contract, with risky clauses flagged.

How do buyers evaluate radiologist retention, and how do I answer it?

Retention is a buyer's number-one question because the radiologists are the revenue, and you answer it with signed agreements and a demonstrably stable panel, not assurances. The market backdrop is why buyers press so hard: radiologist attrition more than doubled from 2014 to 2022, rising from 1.1% to 2.5% per year (Neiman HPI), while supply is projected to grow only 25.7% from 2023 to 2055 against imaging demand rising 16.9% to 26.9% — a persistent shortage. So a buyer scrutinizes your employment and contractor agreements, non-competes, subspecialty depth, and teleradiology dependence. You answer by staging the file cleanly: signed agreements, retention terms surviving closing, and low turnover. An owned, locked panel is worth more because the shortage makes coverage scarce.

Are my two MRIs over 10 years old a deal-breaker on valuation?

Rarely a deal-breaker, but almost always a price adjustment, because buyers deduct near-term replacement capex on an aging fleet. Buyers underwrite each scanner's age, model, coverage level, and remaining service-contract term, and the service contract is the largest predictable equipment expense. Industry sources report OEM MRI service contracts running roughly $150,000-$350,000 per year, with OEM coverage typically costing 40-80% more than third-party ISO providers. Two MRIs past ten years signal looming capex, so a buyer models replacement and subtracts it — not a kill, a haircut. You blunt it by documenting the fleet honestly: install dates, service history, transferable warranties, and recent capex. A transparent, well-maintained fleet defends the multiple; an undisclosed aging fleet discovered in diligence triggers a re-trade.

What EBITDA multiple do outpatient imaging centers sell for in 2026?

There's no single benchmark; the honest answer is that advisors publish ranges — from advisory and valuation marketing, not audited datasets — so treat them as directional. Those frameworks commonly cite roughly 4x-12x EBITDA across US outpatient imaging, with single-site centers reported lower (often 3x-6x) and regional or multi-state platforms reported higher (into the 9x-12x-plus range). Advisors also report that a competitive auction is worth one to three turns of EBITDA over a single-bidder negotiation. What actually sets your number isn't a table — it's whether your data room proves the Big Three: payor-contract survival, radiologist retention, and fleet age. Document all three and you defend the top of the range; fail, and you get repriced toward the bottom.

How much does a virtual data room cost for a healthcare M&A deal?

For a physician-owned imaging group, a flat-rate room runs far below legacy per-page platforms. Peony's Data Room plan is $52 per user per month (its most popular tier) and the Deal Team plan is $64 per user per month with a four-seat minimum; buyers, lawyers, and quality-of-earnings teams view for free as unlimited free viewers, so you pay for your own seats, not the thousands of pages a radiology deal renders into. That fits imaging M&A's heavy document set and small deal team. Legacy platforms like Datasite and Intralinks can bill tens of thousands on the same set. The honest carve: a Lumexa-scale platform sale run by bankers uses an enterprise VDR; a flat-rate room wins the one-to-ten-site physician-owned sell-side.

The bottom line: document the Big Three and the deal closes at the multiple

An imaging-center sale is decided by three questions and a transfer stack, and every one of them is answered with paper. Will the payer contracts survive a change of control, or does consent let a payer reprice away the EBITDA? Are the radiologists locked in against a documented national shortage, or is the panel one departure from collapse? What capex is the fleet hiding, and is it disclosed or waiting to be discovered? And does the regulatory stack — CON, IDTF and the CHOW decision, radioactive-materials and MQSA licenses — transfer cleanly and on schedule? The buyers doing the consolidating in 2026 — a public RadNet at ~435 centers, a newly public Lumexa at 184, a PE-backed SimonMed, a Stonepeak-owned Akumin — are professionalized, and they underwrite those questions rigorously. The seller who answers them in an organized, gated room holds the price it underwrote. The seller who emails PDFs and assembles the room reactively gets repriced one re-trade at a time.

That's the whole thesis: in imaging M&A the data room isn't logistics around the deal — because the value lives in contracts, licenses, and people rather than in the building, the room is where the sale is won or lost. Stage the Big Three and the transfer stack before the request list lands, de-identify the PHI and keep the rest behind a BAA, gate the referral book behind staged disclosure, and match the room to the deal — a flat-rate room for the physician-owned sell-side, an enterprise VDR only at platform scale. Do that, and a radiology-group sale closes cleanly at the multiple. Leave it scattered, and the roll-up wave takes its discount out of your price.

Related resources

• Best healthcare M&A advisors — who should bank your imaging-group sale, by subsector.
• Medical device M&A data room — the sibling healthcare-M&A room for device companies.
• Medical equipment sale data room — selling imaging and diagnostic equipment as an asset.
• Independent sponsor and healthcare capital partners — when a capital partner, not a strategic, is your buyer.
• Due diligence timeline — the standard phases and calendar of an M&A diligence process.
• Skilled nursing facility data room — the licensed-healthcare cousin, where the CHOW is the deal.

Sources

• National Conference of State Legislatures (NCSL) — Certificate of Need State Laws (35 states + D.C. as of 2025)
• North Carolina Division of Health Service Regulation — Certificate of Need program and 2025 fixed-MRI certificate issuances
• Centers for Medicare & Medicaid Services — Form CMS-855B, Medicare Enrollment Application for Clinics/Group Practices and IDTFs
• CMS Medicare Coverage Database — IDTF Local Coverage Determination (30/90-day reporting rule; performance standards)
• Neiman Health Policy Institute — Future radiologist workforce supply and demand; attrition and shortage projections (Feb. 12, 2025)
• Federal Register — Removal of the Non-Compete Rule (16 CFR Part 910) from the CFR, effective Feb. 12, 2026 (notice 2026-02866)
• U.S. Nuclear Regulatory Commission — Agreement States (39 as of March 2025; ~88% of radioactive-material licenses)
• U.S. Food & Drug Administration — Mammography Quality Standards Act (MQSA) and the public, ZIP-searchable certified-facility database
• U.S. Department of Health & Human Services, Office for Civil Rights — HIPAA de-identification (Safe Harbor, 18 identifiers) and Business Associate guidance
• RadNet, Inc. — Q1 2026 results and 2026 acquisition activity (center count, revenue)
• U.S. Securities and Exchange Commission — Lumexa Imaging (formerly US Radiology Specialists) Form S-1 (renaming July 8, 2025; 184 centers, 13 states, Sept. 30, 2025)
• Radiology Business — Private-equity activity in diagnostic imaging (2025-2026) and RadNet acquisition reporting Disclosure: I'm the co-founder of Peony, a virtual data room company, so I have an interest in how this turns out. I've tried to keep the analysis honest — including conceding that a Lumexa-scale platform sale run by its bankers defaults to an enterprise VDR like Datasite or Intralinks, and that the deep advisory and valuation frameworks are owned by the M&A advisors and law firms. Published EBITDA multiples come from advisory and valuation marketing pages, not audited datasets, and are presented as directional ranges only; equipment-service and consolidation figures tagged "reported" come from trade press or vendor sources and should be verified against primary filings for a live deal. Specific regulations, CMS forms, and figures were checked against the sources above as of July 2026; healthcare regulation is precise and changes. None of this is legal, tax, or investment advice — engage qualified healthcare-transaction counsel for your deal.